天津招聘

(Sr.) SP Manager in strategic planning (commercial/ portfolio/ manufacturing)

主要职责：
You will support targeted, effective and efficient strategic planning and management by sourcing, synthesizing, summarizing, and providing key business analytics that enable informed decision-making that affect the overall Henlius corporate strategy from the angle of portfolio, manufacturing and commercialization. You will provide objective information and insights using data and analytical techniques that support cross-functional stakeholders, including product development, regulatory affairs, portfolio management, manufacturing, marketing, pricing & market access teams.
? Conduct commercial assessment and insights for candidate molecule/ disease area/ indication to shape the portfolio
o Communicate with Portfolio Governess Committee business manager on roadmap update
o Synthesize information for insight generation
o Integrate market data to support forecast modeling
o Work closely with brand team and finance team on forecast modeling
o Track and update competitive intelligence on a regular basis
? Provide strategic recommendations to senior leadership via detailed assessment on latest market trends
o Support refining market research methodology for internal business needs
o Work with vendors to ensure high-quality deliverables
? Work closely with cross-functional teams on strategy generation, shaping and implementation 
o Coordinate cross-functional strategic & business planning and review cycles
o Engage and manage senior key stakeholders to achieve alignment
? Develop and manage corporate initiatives serving the company’s objectives

任职条件
？ 教育要求： 
? Bachelor’s degree or above, with major in marketing, business, or science. A postgraduate degree (e.g. MSc, PhD, or MBA) is preferred.

？ 工作经验要求：
? Post-BSc with 1 – 2 years (3+ for Sr. SPM) working experience in a consulting firm or/and corporate strategy related functions
? Rich experience in healthcare, preferably pharmaceuticals

？ 岗位技能要求：
? Proven experience and skills in project management, financial modeling, project management, and presentation
? Strong data processing and desk research capability
? Good communication skills
? Good spoken and written English level
? Good PowerPoint and Excel skills

？ 其他要求：
? Have knowledge about China pharmaceutical industry (> 1-year experience in MNCs or healthcare consulting companies)
? Clinical trial paper understanding or can read/understand clinical trials

Additional Notes: POSITION TO START AS SOON AS POSSIBLE.

    复宏汉霖（*******）是一家国际化的创新生物制药公司，旨在为全球患者提供质高价优的创新生物药，产品覆盖肿瘤、自身免疫性疾病等领域。自2010年成立以来，公司以全球联动、整合创新为产品开发理念，在中国上海、中国台北和美国加州均设有研发中心，具备了协同增效的突出优势。复宏汉霖主要的产品开发策略是仿创结合，从生物类似药起步，逐步开发创新型单抗产品，结合自主开发的抗PD-1和PD-L1单抗，在国内率先推出免疫联合疗法，前瞻性布局了一个多元化、创新单抗及肿瘤免疫联合疗法管线，打造出研究、开发、商业化生产的综合性生物医药全产业链平台。

    截至目前，复宏汉霖已有1个产品成功上市，2个产品获得中国新药上市申请受理，1个产品获得欧盟营销授权申请受理，10个产品、8个联合治疗方案在全球范围内开展20多项临床试验。其中，公司首款重磅产品汉利康？（利妥昔单抗注射液）于2019年2月获国家药监局新药上市注册批准，成为中国***获批上市的生物类似药。HLX03（阿达木单抗注射液）与HLX02（注射用曲妥珠单抗）已获国家药监局新药上市申请受理，现已纳入优先审评程序。HLX02相继在中国大陆、乌克兰、欧盟波兰和菲律宾全面启动国际多中心3期临床试验，成为国内***开展国际多中心3期临床研究的生物类似药，并于2019年6月获欧洲药品管理局营销授权申请受理。此外，公司已陆续就HLX10（抗PD-1单抗）与自有产品HLX04（贝伐珠单抗生物类似药）、HLX07（抗EGFR单抗）以及化疗联用开展多项肿瘤免疫联合疗法，在全球范围内开展多个临床研究。